Mutual Regulation Between N6-methyladenosine (m6A) Modification and Circular RNAs in Cancer: Impacts on Therapeutic Resistance

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2022 Jul 17

PMID 35843942

Authors

Hong Lin

Yuxi Wang

Pinghan Wang

Fangyi Long

Ting Wang

Affiliations

Soon will be listed here.

Abstract

The resistance of tumor cells to therapy severely impairs the efficacy of treatment, leading to recurrence and metastasis of various cancers. Clarifying the underlying mechanisms of therapeutic resistance may provide new strategies for overcoming cancer resistance. N6-methyladenosine (m6A) is the most prevalent RNA modification in eukaryotes, and is involved in the regulation of RNA splicing, translation, transport, degradation, stability and processing, thus affecting several physiological processes and cancer progression. As a novel type of multifunctional non-coding RNAs (ncRNAs), circular RNAs (circRNAs) have been demonstrated to play vital roles in anticancer therapy. Currently, accumulating studies have revealed the mutual regulation of m6A modification and circRNAs, and their interaction can further influence the sensitivity of cancer treatment. In this review, we mainly summarized the recent advances of m6A modification and circRNAs in the modulation of cancer therapeutic resistance, as well as their interplay and potential mechanisms, providing promising insights and future directions in reversal of therapeutic resistance in cancer.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.

Recent Advances in the Mutual Regulation of m6A Modification and Non-Coding RNAs in Atherosclerosis.

Wang Y, Ling S, Feng H, Hua J, Han Z, Chai R Int J Gen Med. 2025; 18:1047-1073.

PMID: 40026815 PMC: 11871936. DOI: 10.2147/IJGM.S508197.

Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.

Li P, Fang X, Huang D Eur J Med Res. 2025; 30(1):98.

PMID: 39940056 PMC: 11823136. DOI: 10.1186/s40001-025-02353-5.

New insights into N6-methyladenosine in hepatocellular carcinoma immunotherapy.

Li M, Tian H, Zhuang Y, Zhang Z Front Immunol. 2025; 16:1533940.

PMID: 39911396 PMC: 11794227. DOI: 10.3389/fimmu.2025.1533940.

circTP63-N suppresses the proliferation and metastasis of nasopharyngeal carcinoma via engaging with HSP90AB1 to modulate the YAP1/Hippo signaling pathway.

Wang D, Zuo S, Ge J, Qu H, Wu J, Yi N Sci China Life Sci. 2025; 68(3):689-705.

PMID: 39754006 DOI: 10.1007/s11427-023-2737-2.

References

Wang X, Cao Q, Shi Y, Wu X, Mi Y, Liu K . Identification of low-dose radiation-induced exosomal circ-METRN and miR-4709-3p/GRB14/PDGFRα pathway as a key regulatory mechanism in Glioblastoma progression and radioresistance: Functional validation and clinical theranostic significance. Int J Biol Sci. 2021; 17(4):1061-1078. PMC: 8040305. DOI: 10.7150/ijbs.57168. View

He X, Ma J, Zhang M, Cui J, Yang H . Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis. Cancer Biomark. 2020; 29(4):531-542. DOI: 10.3233/CBM-200023. View

Schmidt C, Giusto J, Bao A, Hopper A, Matera A . Molecular determinants of metazoan tricRNA biogenesis. Nucleic Acids Res. 2019; 47(12):6452-6465. PMC: 6614914. DOI: 10.1093/nar/gkz311. View

Jian X, He H, Zhu J, Zhang Q, Zheng Z, Liang X . Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340. Mol Cancer. 2020; 19(1):20. PMC: 6993513. DOI: 10.1186/s12943-020-1134-8. View

Salehan M, Morse H . DNA damage repair and tolerance: a role in chemotherapeutic drug resistance. Br J Biomed Sci. 2013; 70(1):31-40. DOI: 10.1080/09674845.2013.11669927. View

Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y . Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018; 17(1):120. PMC: 6087002. DOI: 10.1186/s12943-018-0869-y. View

Cittelly D, Das P, Salvo V, Fonseca J, Burow M, Jones F . Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010; 31(12):2049-57. PMC: 2994280. DOI: 10.1093/carcin/bgq192. View

Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y . ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Mol Med Rep. 2014; 9(6):2423-8. DOI: 10.3892/mmr.2014.2112. View

Qiu X, Yang S, Wang S, Wu J, Zheng B, Wang K . MA Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma. Cancer Res. 2021; 81(18):4778-4793. DOI: 10.1158/0008-5472.CAN-21-0468. View

10.

Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J . CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mA modification in hepatocellular carcinoma. Mol Ther Oncolytics. 2022; 24:755-771. PMC: 8908059. DOI: 10.1016/j.omto.2022.02.021. View

11.

Xu X, Zhang J, Tian Y, Gao Y, Dong X, Chen W . CircRNA inhibits DNA damage repair by interacting with host gene. Mol Cancer. 2020; 19(1):128. PMC: 7446195. DOI: 10.1186/s12943-020-01246-x. View

12.

Lee Y, Choe J, Park O, Kim Y . Molecular Mechanisms Driving mRNA Degradation by mA Modification. Trends Genet. 2020; 36(3):177-188. DOI: 10.1016/j.tig.2019.12.007. View

13.

Lord C, Ashworth A . The DNA damage response and cancer therapy. Nature. 2012; 481(7381):287-94. DOI: 10.1038/nature10760. View

14.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

15.

Jiang X, Guo S, Wang S, Zhang Y, Chen H, Wang Y . EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling. Cancer Res. 2021; 82(5):831-845. DOI: 10.1158/0008-5472.CAN-21-2988. View

16.

Hong C, Lishan W, Peng X, Zhengqing L, Yang Y, Fangfang H . Hsa_circ_0074298 promotes pancreatic cancer progression and resistance to gemcitabine by sponging miR-519 to target SMOC. J Cancer. 2022; 13(1):34-50. PMC: 8692684. DOI: 10.7150/jca.62927. View

17.

Li J, Sun D, Pu W, Wang J, Peng Y . Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance. Trends Cancer. 2020; 6(4):319-336. DOI: 10.1016/j.trecan.2020.01.012. View

18.

Nombela P, Miguel-Lopez B, Blanco S . The role of mA, mC and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 2021; 20(1):18. PMC: 7812662. DOI: 10.1186/s12943-020-01263-w. View

19.

Koukourakis M, Giatromanolaki A, Panteliadou M, Pouliliou S, Chondrou P, Mavropoulou S . Lactate dehydrogenase 5 isoenzyme overexpression defines resistance of prostate cancer to radiotherapy. Br J Cancer. 2014; 110(9):2217-23. PMC: 4007238. DOI: 10.1038/bjc.2014.158. View

20.

Wen J, Zhao M . OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma. Dis Markers. 2021; 2021:9711179. PMC: 8550862. DOI: 10.1155/2021/9711179. View